MXPA01012936A - Composicion farmaceutica que contiene sibutramina y orlistat. - Google Patents

Composicion farmaceutica que contiene sibutramina y orlistat.

Info

Publication number
MXPA01012936A
MXPA01012936A MXPA01012936A MXPA01012936A MXPA01012936A MX PA01012936 A MXPA01012936 A MX PA01012936A MX PA01012936 A MXPA01012936 A MX PA01012936A MX PA01012936 A MXPA01012936 A MX PA01012936A MX PA01012936 A MXPA01012936 A MX PA01012936A
Authority
MX
Mexico
Prior art keywords
compound
formula
orlistat
pharmaceutical composition
composition containing
Prior art date
Application number
MXPA01012936A
Other languages
English (en)
Spanish (es)
Inventor
David John Heal
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of MXPA01012936A publication Critical patent/MXPA01012936A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA01012936A 1999-06-24 2000-06-16 Composicion farmaceutica que contiene sibutramina y orlistat. MXPA01012936A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9914744.9A GB9914744D0 (en) 1999-06-24 1999-06-24 Therapeutic agents
PCT/EP2000/005542 WO2001000205A1 (en) 1999-06-24 2000-06-16 Pharmaceutical composition containing sibutramine and orlistat

Publications (1)

Publication Number Publication Date
MXPA01012936A true MXPA01012936A (es) 2004-04-21

Family

ID=10855955

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01012936A MXPA01012936A (es) 1999-06-24 2000-06-16 Composicion farmaceutica que contiene sibutramina y orlistat.

Country Status (21)

Country Link
EP (1) EP1187606A1 (bg)
JP (1) JP2003503349A (bg)
KR (1) KR20020015357A (bg)
CN (1) CN1358092A (bg)
AU (1) AU5533200A (bg)
BG (1) BG106180A (bg)
BR (1) BR0011880A (bg)
CA (1) CA2375972A1 (bg)
CZ (1) CZ20014613A3 (bg)
GB (1) GB9914744D0 (bg)
HK (1) HK1049278A1 (bg)
HU (1) HUP0201878A3 (bg)
IL (1) IL147079A0 (bg)
MX (1) MXPA01012936A (bg)
NO (1) NO20016224L (bg)
PL (1) PL352402A1 (bg)
RU (1) RU2229289C2 (bg)
SK (1) SK18242001A3 (bg)
TR (1) TR200103699T2 (bg)
WO (1) WO2001000205A1 (bg)
ZA (1) ZA200109989B (bg)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US20040214804A1 (en) * 2003-04-25 2004-10-28 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-obesity agent
BRPI0517434A (pt) 2004-10-25 2008-10-07 Solvay Pharm Gmbh composições farmacêuticas compreendendo antagonistas do receptor canabinóide cb1 e abridores de canal de potássio para o tratamento de diabetes mellitus do tipo i, obesidade e estados relacionados
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
CA2663254C (en) 2006-09-15 2016-04-19 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
KR20080046601A (ko) * 2006-11-22 2008-05-27 에스케이케미칼주식회사 보관안정성이 우수한 시부트라민 함유 포접복합체
CN101890017A (zh) * 2009-05-22 2010-11-24 北京奥萨医药研究中心有限公司 含有西布曲明和他汀类降脂药物的药物组合物及其用途
MX336980B (es) * 2010-12-21 2016-02-09 Senosiain S A De C V Lab Combinacion y composicion para el tratamiento de obesidad.
RU2642074C2 (ru) 2011-12-30 2018-01-24 Ревива Фармасьютикалс, Инк. Композиции, синтез и способы применения производных фенилциклоалкилметиламина

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727131D0 (en) * 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
GB9914744D0 (en) 1999-08-25
SK18242001A3 (sk) 2003-02-04
BG106180A (bg) 2002-08-30
TR200103699T2 (tr) 2002-04-22
HK1049278A1 (zh) 2003-05-09
CA2375972A1 (en) 2001-01-04
EP1187606A1 (en) 2002-03-20
HUP0201878A2 (hu) 2003-08-28
IL147079A0 (en) 2002-08-14
WO2001000205A1 (en) 2001-01-04
HUP0201878A3 (en) 2005-04-28
AU5533200A (en) 2001-01-31
NO20016224D0 (no) 2001-12-19
CZ20014613A3 (cs) 2003-04-16
CN1358092A (zh) 2002-07-10
RU2229289C2 (ru) 2004-05-27
KR20020015357A (ko) 2002-02-27
PL352402A1 (en) 2003-08-25
BR0011880A (pt) 2002-03-19
ZA200109989B (en) 2003-02-26
JP2003503349A (ja) 2003-01-28
NO20016224L (no) 2002-02-12

Similar Documents

Publication Publication Date Title
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
EG25822A (en) Quinolinyl-pyrrolopyrazoles
GEP20043324B (en) Purine Derivatives
GB2254784B (en) Film-coated solid dosage form of anti-migraine drug
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
AU3850600A (en) Dalda analogs and their use
MXPA01012936A (es) Composicion farmaceutica que contiene sibutramina y orlistat.
WO2001000187A3 (en) Pharmaceutical composition containing sibutramine and a lipase inhibitor
TW200517127A (en) Novel composition
WO2005055933A3 (en) Treatment of psoriasis with rosiglitazone
AP9801235A0 (en) Erythromycin derivatives.
SE9800905D0 (sv) New therapy in glomerulonephritis
YU25202A (sh) Supstituisani piroli kao antiproliferativna sredstva za lečenje kancera
MY126998A (en) Substituted pyrroles.
EP1347754A4 (en) COMPOSITIONS FOR PREVENTION OF ADHESION
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors
JO2360B1 (en) Substituted pyrolates
WO2003004019A8 (en) Use of heterocyclic and benzoheterocyclic polyamides structurally related to the natural antibiotic distamycin a for the treatment of beta-thalassaemia